Arica, VefikTutanc, MuratOzturk, Oktay HasanArica, SecilBasarslan, FatmagulErden, Ersin SukruOktar, Suleyman2024-09-182024-09-1820110960-3271https://doi.org/10.1177/0960327110396526https://hdl.handle.net/20.500.12483/9877Aim: In the study, we examined erdosteine's effects on platelet functions and coagulation. Materials and methods: A total 29 young albino Wistar rats were divided into four groups. Control rats (n = 6) were given saline; Group I rats (n = 7) were given 3 mg/kg erdosteine by oral gavage for 3 days; Group 2 rats (n = 7) were given 10 mg/kg erdosteine by oral gavage for 3 days; and Group 3 rats (n = 9) were given 30 mg/kg erdosteine for 3 days. Twenty-four hours after the final dose, blood samples were drawn from a portal vein. Prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR) were measured, and platelet counts were examined in a peripheral blood smear by light microscopy. Results: PT and INR values of Group I increased compared to the controls but did not change in Group 3. Hemostatic parameters were not measured in Group 2 because the blood samples in Group 2's tubes clotted rapidly. Platelet counts of the peripheral blood from Group 2 were low but were normal in other groups. Conclusion: We have concluded erdosteine may disrupt hemostasis parameters by its different metabolites in patients. Erdosteine has dual effects on hemostasis via its different metabolites, which occur in different doses.eninfo:eu-repo/semantics/closedAccesserdosteinehemostasisbleedingclottingArticle30101644164810.1177/0960327110396526212479892-s2.0-80054854936Q2WOS:000295812200025Q3